Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

G M Eliopoulos 1, K Klimm 1, C T Eliopoulos 1, M J Ferraro 1, R C Moellering Jr 1
PMCID: PMC187672  PMID: 8452372

Abstract

The in vitro activity of the fluoroquinolone CP-99,219 against gram-positive bacteria was compared with those of five other antimicrobial agents. Against ciprofloxacin-susceptible staphylococci and against streptococci, MICs were < or = 0.12 and < or = 0.5 microgram/ml, respectively. CP-99,219 was also more active than ciprofloxacin against ciprofloxacin-resistant staphylococci, most enterococci, Leuconostoc spp., and lactobacilli.

Full text

PDF
366

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother. 1982 Feb;9 (Suppl 100):143–152. doi: 10.1093/jac/9.suppl_c.143. [DOI] [PubMed] [Google Scholar]
  2. Eliopoulos G. M., Klimm K., Rice L. B., Ferraro M. J., Moellering R. C., Jr Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother. 1990 Jun;34(6):1154–1159. doi: 10.1128/aac.34.6.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fuchs P. C., Barry A. L., Pfaller M. A., Allen S. D., Gerlach E. H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991 Apr;35(4):764–766. doi: 10.1128/aac.35.4.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Grayson M. L., Eliopoulos G. M., Wennersten C. B., Ruoff K. L., Klimm K., Sapico F. L., Bayer A. S., Moellering R. C., Jr Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother. 1991 Jul;35(7):1408–1412. doi: 10.1128/aac.35.7.1408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Miranda A. G., Wanger A. R., Singh K. V., Murray B. E. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992 Jun;36(6):1325–1328. doi: 10.1128/aac.36.6.1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Murray B. E., Mederski-Samaroj B. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest. 1983 Sep;72(3):1168–1171. doi: 10.1172/JCI111042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Rhinehart E., Smith N. E., Wennersten C., Gorss E., Freeman J., Eliopoulos G. M., Moellering R. C., Jr, Goldmann D. A. Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med. 1990 Dec 27;323(26):1814–1818. doi: 10.1056/NEJM199012273232606. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES